SCNX logo

SCIENTURE HOLDINGS INC

SCNXNASDAQ
πŸ† #4195 by market capEarnings Aug 17US Equity
$0.40β–Ό $0.01 (βˆ’2.91%)
Live
1hβ–² 5.2%
24hβ–Ό 2.9%
7dβ–² 3.8%
14dβ–² 11.9%
30dβ–² 14.8%
1yβ–Ό 81.3%
🏦Market Cap
$16M
Small Cap
πŸ“ˆRevenue Growth (YoY)
+215.9%
High Growth
πŸ“ŠGross Margin
-20.7%
Thin
πŸ’΅FCF Margin
-2793.2%
Thin
βš–οΈP/S Ratio
33.8x
Expensive
Otter Score
61
Fair

Trading Snapshot

Day Range
$0.39 – $0.40
52-Week Range
$0.24 – $2.60
Volume
$3.56B
Avg Volume
$3.87B
Shares Outstanding
40.6M
Next Earnings
Oct 20, 2026

Fundamentals Snapshot

Annual Revenue
$431,609
Last Q Revenue
$56,325
P/E Ratio
-0.2
P/S Ratio
33.8x
EPS (TTM)
$-0.10
Dividend Yield
0.00%

Why Investors Own SCNX

  • βœ“High-growth profile β€” revenue up +45.1% YoY with expanding US Equity exposure.
  • βœ“Healthy economics β€” 44% gross margin and 26% free-cash-flow margin.
  • βœ“New products and segments could unlock additional revenue streams.
⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

Financial Trends

Revenue (TTM)
$431,609β–² +40.2% YoY
Gross Margin (TTM)
44.1%β–² +0.1% YoY
Operating Income (TTM)
$152,358β–² +40.2% YoY
Free Cash Flow (TTM)
$110,492β–² +40.2% YoY

About SCIENTURE HOLDINGS INC

As a health services IT enterprise, TRxADE HEALTH, Inc. manages an online platform designed to facilitate transactions between licensed pharmaceutical wholesalers and healthcare providers. This digital marketplace enables wholesalers to distribute a broad spectrum of products and services, encompassing branded and generic drugs as well as other non-pharmaceutical items. Customers for these offerings span government organizations, hospitals, medical clinics, and independent pharmacies. The firm's corporate base is situated in Tampa, Florida.

🦦

Otter Score Breakdown

β“˜
πŸ’ŽQualityβ˜…β˜…β˜…β˜…β˜…
πŸš€Growthβ˜…β˜…β˜…β˜…β˜…
βš–οΈValuationβ˜…β˜…β˜…β˜…β˜…
⚑Momentumβ˜…β˜…β˜…β˜…β˜…
Overall Score
Fair
61/100

Analyst Price Target

β“˜
Average Target
$0.49
β–² +22.3% Upside
High Target$0.60
Low Target$0.45
Based on 36 analysts

Latest News & Updates